Cite
Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2021;10(1):11-25doi: 10.1016/S2213-2600(21)00322-2.
Wechsler, M. E., Ford, L. B., Maspero, J. F., Pavord, I. D., Papi, A., Bourdin, A., Watz, H., Castro, M., Nenasheva, N. M., Tohda, Y., Langton, D., Cardona, G., Domingo, C., Park, H. S., Chapman, K. R., Mao, X., Zhang, Y., Khan, A. H., Deniz, Y., Rowe, P. J., Kapoor, U., Khokhar, F. A., Mannent, L. P., Ruddy, M., Laws, E., Amin, N., & Hardin, M. (2022). Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. The Lancet. Respiratory medicine, 10(1), 11-25. https://doi.org/10.1016/S2213-2600(21)00322-2
Wechsler, Michael E, et al. "Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study." The Lancet. Respiratory medicine vol. 10,1 (2022): 11-25. doi: https://doi.org/10.1016/S2213-2600(21)00322-2
Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A, Watz H, Castro M, Nenasheva NM, Tohda Y, Langton D, Cardona G, Domingo C, Park HS, Chapman KR, Mao X, Zhang Y, Khan AH, Deniz Y, Rowe PJ, Kapoor U, Khokhar FA, Mannent LP, Ruddy M, Laws E, Amin N, Hardin M. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022 Jan;10(1):11-25. doi: 10.1016/S2213-2600(21)00322-2. Epub 2021 Sep 28. PMID: 34597534.
Copy
Download .nbib